The National Association of Pharmacy Regulatory Authorities (NAPRA) of Canada published revised Models of Standards for the compounding of sterile, non-sterile (draft), hazardous, and non-hazardous preparations. The purpose of these new guidelines is to provide standards and define processes to protect personnel, patients, and the environment when handling Hazardous Drugs in a healthcare setting. The guidelines provide a comprehensive approach for handling Hazardous Drugs with the ultimate goal of preventing and/or minimizing exposure to Hazardous Drugs.

Are you currently compounding with any hazardous active pharmaceutical ingredients such as Apomorphone, Azathioprin, Cyclophosphamide, Cyclosporine, Diethylstilbestrol, Estradiol, Fluorouracil, Medroxyprogesterone, Phenytoin, Progesterone, Spironolactone, or Tacrolimus? If so, it is important to start thinking of the changes required to your practice in order to become compliant with these new standards once they are approved and implemented by your respective provincial regulatory body.

Explore hazardous chemicals, devices and equipment for use with Hazardous Compounding, and find answers to frequently asked questions about NAPRA’s guidelines.

Hazardous Chemicals

View a list of the drugs supplied by MEDISCA that are currently on the NIOSH list of Antineoplastic and Other Hazardous Drugs in Healthcare Settings.


Equipment & Devices for Hazardous Compounding

Special precautions must be taken when handling hazardous chemicals. Learn more about the equipment and devices that can help prevent or minimize your exposure. Our products include Personal Protective Equipment, Closed System Transfer Devices, Emergency Equipment, Deactivation Agents, and more.


Hazardous Drug Compounding FAQ (Frequently Asked Questions)

What is Hazardous Compounding? When do the new NAPRA guidelines come into effect? What kind of equipment do I need to use with hazardous chemicals? Find in our FAQ section answers to common questions about NAPRA’s Model Standards for Pharmacy Compounding and how they will impact your compounding pharmacy practice.


1On September 29th, 2017 USP released a notification of intent to revise the official implementation date of USP General Chapter <800> to December 1, 2019.



We have placed cookies on your device to help make this website better.

We also use cookies to collect information for making reports and to help us improve the site. The cookies collect information in an anonymous form.

Copyright® 1986-2019 Medisca Inc.
All rights reserved

MEDISCA is ISO 9001:2008 certified